Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$12100.00
-780.00 (-6.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-8.4B · quality 75.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$267.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.6%
↓Gross Margin
23.1%
↓Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.1%
FCF CAGR
—
FCF margin
-58.7%
FCF / Net income
0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.67B · net income $-11.25B · FCF $-10.95B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.67B | $18.67B | $17.29B | $13.97B | $12.57B |
| Net Income | $-11.25B | $-11.25B | $-9.42B | $-6.71B | $-13.96B |
| EBITDA | $-4.87B | $-4.87B | $-2.61B | $-566.3M | $-8.04B |
| EPS | -508.00 | -508.00 | -426.00 | -304.00 | -732.00 |
| Gross Margin | 23.1% | 23.1% | 17.5% | 11.2% | 13.6% |
| Operating Margin | -41.5% | -41.5% | -54.7% | -60.2% | -102.8% |
| Net Margin | -60.3% | -60.3% | -54.5% | -48.0% | -111.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.14 | 0.14 | 0.07 | 0.06 | 0.17 |
| Current Ratio | 3.01 | 3.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.95B | $-10.95B | $-5.09B | $-8.44B | $-11.57B |
| Returns | |||||
| ROE | -20.6% | -20.6% | -17.3% | -10.5% | -19.9% |
| Valuation | |||||
| P/B | 4.90 | 4.90 | 7.18 | 3.54 | 2.63 |
| Growth & Yield | |||||
| Revenue Growth | 8.0% | 8.0% | 23.8% | 11.1% | — |
| EPS Growth | -19.2% | -19.2% | -40.1% | 58.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-426.00 → -508.00
Residual
-29.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.